Evidence map›Paper›PMID 41295513›Full record

ReviewVaccines2025

Antiviral Inactivated Vaccines: Looking to the Past to Face the Future-A Narrative Review.

Francisca Hildemagna Guedes-da-Silva, Victor Augusto Roncaglia-Pereira, Sara Torres, María Camila Escobar García, Kelvinson Fernandes Viana, Jerson Lima Silva, Andréa Cheble Oliveira, Andre Marco Oliveira Gomes

Abstract readReview
In one paragraph

Review in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francisca Hildemagna Guedes-da-SilvaInstitute of Medical Biochemistry Leopoldo de Meis and National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0003-1026-0917
Victor Augusto Roncaglia-PereiraInstitute of Medical Biochemistry Leopoldo de Meis and National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0002-5160-8062
Sara TorresVaccine Development Technology Laboratory, Federal University for Latin American Integration (UNILA), Foz do Iguaçu 85870-650, PR, Brazil.
María Camila Escobar GarcíaVaccine Development Technology Laboratory, Federal University for Latin American Integration (UNILA), Foz do Iguaçu 85870-650, PR, Brazil.
Kelvinson Fernandes VianaVaccine Development Technology Laboratory, Federal University for Latin American Integration (UNILA), Foz do Iguaçu 85870-650, PR, Brazil.ORCID 0000-0002-4657-5446
Jerson Lima SilvaInstitute of Medical Biochemistry Leopoldo de Meis and National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0001-9523-9441
Andréa Cheble OliveiraInstitute of Medical Biochemistry Leopoldo de Meis and National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0003-4381-9908
Andre Marco Oliveira GomesInstitute of Medical Biochemistry Leopoldo de Meis and National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0003-1052-8004

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior (CAPES)Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/200.340/2023National Council for Scientific and Technological Development CNPq awards and INCT Program
6 · The paper itself

Abstract

Throughout human history, contagious infectious diseases have significantly impacted societies, shaping the fate of great dynasties and challenging economic and political systems, social relations, and the overall well-being of the human species. The SARS-CoV-2 pandemic brought unprecedented challenges, emerging in the context of extreme globalization and rapid technological development. The speed of viral spread, the highest absolute mortality rate caused by a viral agent in the last 100 years, and the severe economic and social consequences imposed an urgent need for vaccine development on a previously unimaginable timescale. The proven safety and efficacy of inactivated vaccines enabled the development and large-scale application of the first immunizer against SARS-CoV-2 in less than a year after the World Health Organization (WHO) declared the pandemic. In this review, we discuss the importance of inactivated antiviral vaccines and their historical impact in containing highly harmful diseases affecting humanity. We also explore the cellular mechanisms by which inactivated vaccines may induce immunogenic responses against viral pathogens. In addition, we bring to light a discussion about a fast, cost-effective, potentially efficient technology for large-scale immunizer production: High hydrostatic pressure (HHP), a method long supported by decades of preclinical studies and which is especially effective in the context of enveloped viruses. Finally, we discuss the role of inactivated antiviral vaccines in the face of advances in biotechnology and, therefore, the emergence of vaccines that use genetic engineering in their production, such as RNA, DNA and viral vaccines, which have gained special prominence during the COVID-19 pandemic.

Indexed as

high hydrostatic pressureimmunizersinactivated vaccinesvirus

Identifiers

PMID41295513
PMCPMC12656770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.